Cargando…

Fluorescent base analogues in gapmers enable stealth labeling of antisense oligonucleotide therapeutics

To expand the antisense oligonucleotide (ASO) fluorescence labeling toolbox beyond covalent conjugation of external dyes (e.g. ATTO-, Alexa Fluor-, or cyanine dyes), we herein explore fluorescent base analogues (FBAs) as a novel approach to endow fluorescent properties to ASOs. Both cytosine and ade...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nilsson, Jesper R., Baladi, Tom, Gallud, Audrey, Baždarević, Dženita, Lemurell, Malin, Esbjörner, Elin K., Wilhelmsson, L. Marcus, Dahlén, Anders
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8166847/ https://www.ncbi.nlm.nih.gov/pubmed/34059711 http://dx.doi.org/10.1038/s41598-021-90629-1

Ejemplares similares

Stealth Fluorescence Labeling for Live Microscopy Imaging of mRNA Delivery
por: Baladi, Tom, et al.
Publicado: (2021)

Effects of combinations of gapmer antisense oligonucleotides on the target reduction
por: Yanagidaira, Mitsugu, et al.
Publicado: (2023)

Reduction of Off-Target Effects of Gapmer Antisense Oligonucleotides by Oligonucleotide Extension
por: Yasuhara, Hidenori, et al.
Publicado: (2022)

Novel endosomolytic compounds enable highly potent delivery of antisense oligonucleotides
por: Bost, Jeremy P., et al.
Publicado: (2022)

Towards next generation antisense oligonucleotides: mesylphosphoramidate modification improves therapeutic index and duration of effect of gapmer antisense oligonucleotides
por: Anderson, Brooke A, et al.
Publicado: (2021)

Identification of nucleobase chemical modifications that reduce the hepatotoxicity of gapmer antisense oligonucleotides
por: Yoshida, Tokuyuki, et al.
Publicado: (2022)

Evaluation of off‐target effects of gapmer antisense oligonucleotides using human cells
por: Yoshida, Tokuyuki, et al.
Publicado: (2019)

Understanding the effect of controlling phosphorothioate chirality in the DNA gap on the potency and safety of gapmer antisense oligonucleotides
por: Østergaard, Michael E, et al.
Publicado: (2020)

A cytoplasmic pathway for gapmer antisense oligonucleotide-mediated gene silencing in mammalian cells
por: Castanotto, Daniela, et al.
Publicado: (2015)

Likelihood of Nonspecific Activity of Gapmer Antisense Oligonucleotides Is Associated with Relative Hybridization Free Energy
por: Watt, Andrew T., et al.
Publicado: (2020)

A Versatile and Convenient Synthesis of (34)S‐Labeled Phosphorothioate Oligonucleotides
por: Stulz, Rouven, et al.
Publicado: (2018)

Structure Activity Relationships of α-L-LNA Modified Phosphorothioate Gapmer Antisense Oligonucleotides in Animals
por: Seth, Punit P, et al.
Publicado: (2012)

Bolaamphiphile-based nanocomplex delivery of phosphorothioate gapmer antisense oligonucleotides as a treatment for Clostridium difficile
por: Hegarty, John P, et al.
Publicado: (2016)

Antiviral Efficacy of RNase H-Dependent Gapmer Antisense Oligonucleotides against Japanese Encephalitis Virus
por: Okamoto, Shunsuke, et al.
Publicado: (2023)

Ribonuclease H1-dependent hepatotoxicity caused by locked nucleic acid-modified gapmer antisense oligonucleotides
por: Kasuya, Takeshi, et al.
Publicado: (2016)

A gapmer antisense oligonucleotide targeting SRRM4 is a novel therapeutic medicine for lung cancer
por: Shimojo, Masahito, et al.
Publicado: (2019)

Intratracheally administered LNA gapmer antisense oligonucleotides induce robust gene silencing in mouse lung fibroblasts
por: Shin, Minwook, et al.
Publicado: (2022)

Gapmer Antisense Oligonucleotides Suppress the Mutant Allele of COL6A3 and Restore Functional Protein in Ullrich Muscular Dystrophy
por: Marrosu, Elena, et al.
Publicado: (2017)

Antisense oligonucleotide gapmers containing phosphoryl guanidine groups reverse MDR1-mediated multiple drug resistance of tumor cells
por: Kupryushkin, Maxim S., et al.
Publicado: (2021)

Interbase-FRET binding assay for pre-microRNAs
por: Bood, Mattias, et al.
Publicado: (2021)

Towards Zwitterionic Oligonucleotides with Improved Properties: the NAA/LNA‐Gapmer Approach
por: Wojtyniak, Melissa, et al.
Publicado: (2020)

Hydrogel-Assisted Antisense LNA Gapmer Delivery for In Situ Gene Silencing in Spinal Cord Injury
por: Moreno, Pedro M.D., et al.
Publicado: (2018)

Delivery of Oligonucleotide Therapeutics: Chemical Modifications, Lipid Nanoparticles, and Extracellular Vesicles
por: Bost, Jeremy P., et al.
Publicado: (2021)

Hepatotoxicity of high affinity gapmer antisense oligonucleotides is mediated by RNase H1 dependent promiscuous reduction of very long pre-mRNA transcripts
por: Burel, Sebastien A., et al.
Publicado: (2016)

Antisense Oligonucleotide in LNA-Gapmer Design Targeting TGFBR2—A Key Single Gene Target for Safe and Effective Inhibition of TGFβ Signaling
por: Kuespert, Sabrina, et al.
Publicado: (2020)

Safe and Effective Cynomolgus Monkey GLP—Tox Study with Repetitive Intrathecal Application of a TGFBR2 Targeting LNA-Gapmer Antisense Oligonucleotide as Treatment Candidate for Neurodegenerative Disorders
por: Peters, Sebastian, et al.
Publicado: (2022)

Influence of mismatched and bulged nucleotides on SNP-preferential RNase H cleavage of RNA-antisense gapmer heteroduplexes
por: Magner, Dorota, et al.
Publicado: (2017)

A Sensitive In Vitro Approach to Assess the Hybridization-Dependent Toxic Potential of High Affinity Gapmer Oligonucleotides
por: Dieckmann, Andreas, et al.
Publicado: (2017)

Antisense gapmers selectively suppress individual oncogenic p73 splice isoforms and inhibit tumor growth in vivo
por: Emmrich, Stephan, et al.
Publicado: (2009)

An antisense amido-bridged nucleic acid gapmer oligonucleotide targeting SRRM4 alters REST splicing and exhibits anti-tumor effects in small cell lung cancer and prostate cancer cells
por: Yoshida, Misa, et al.
Publicado: (2023)

Sequence-dependent inhibition of cGAS and TLR9 DNA sensing by 2′-O-methyl gapmer oligonucleotides
por: Valentin, Roxane, et al.
Publicado: (2021)

Efficacy of IAPP suppression in mouse and human islets by GLP-1 analogue conjugated antisense oligonucleotide
por: Gurlo, Tatyana, et al.
Publicado: (2023)

Antisense oligonucleotides in neurological disorders
por: Wurster, Claudia D., et al.
Publicado: (2018)

Molecular Mechanisms of Antisense Oligonucleotides
por: Crooke, Stanley T.
Publicado: (2017)

Antisense oligonucleotides: A primer
por: Scoles, Daniel R., et al.
Publicado: (2019)

Antisense Oligonucleotides and RNA Interference
por: Kher, Gitanjali, et al.
Publicado: (2011)

Antisense Gapmers with LNA-Wings and (S)-5′-C-Aminopropyl-2′-arabinofluoro-nucleosides Could Efficiently Suppress the Expression of KNTC2
por: Zhou, Yujun, et al.
Publicado: (2022)

Microinjection of antisense oligonucleotides into living mouse testis enables lncRNA function study
por: Chen, Zhaohui, et al.
Publicado: (2021)

Opportunities and challenges for antisense oligonucleotide therapies
por: Kuijper, Elsa C., et al.
Publicado: (2020)

Silencing Antibiotic Resistance with Antisense Oligonucleotides
por: Jani, Saumya, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_64ftukdarq3f89vs2j3le25bkh